(MedPage Today) — A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic suppression compared with standard daily oral treatment in an open-label phase II trial.
In 104 virologically…
Nipah virus could turn into something “far more severe”, scientists warn
How South and Southeast Asia respond, will determine whether the zoonotic disease will remain a regional epidemic or escalate dangerously,...






